GGNNQ (Genocea Biosciences) Total Inventories : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Genocea Biosciences Total Inventories?

Genocea Biosciences's total inventories for the quarter that ended in Mar. 2022 was $0.00 Mil. Genocea Biosciences's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Genocea Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $N/A.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genocea Biosciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.00.

Genocea Biosciences Total Inventories Historical Data

The historical data trend for Genocea Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Total Inventories Chart

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Inventories

Get a 7-Day Free Trial

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Genocea Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Genocea Biosciences (OTCPK:GGNNQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Genocea Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is

	Net-Net Working Capital Per Share (Q: Mar. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(20.137	+	0.75 * 0	+	0.5 * 0	-	26.403
-	0	-	0)	/	0
=	N/A

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genocea Biosciences's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2022 )	/	Cost of Goods Sold (Q: Mar. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genocea Biosciences's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2022 )	/	Average Total Inventories (Q: Mar. 2022 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genocea Biosciences's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	0	/	0.27
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Genocea Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GGNNQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.

Executives

John Lunger	director	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Gisela Schwab	director	6701 KAISER DRIVE, FREMONT CA 94555
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Girish N Aakalu	officer: CHIEF BUSINESS OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Narinderjeet Singh	officer: SENIOR VP, PS&M	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Pamela Carroll	officer: SVP IMMUNO-ONCOLOGY	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Thomas Andrew Davis	officer: CHIEF MEDICAL OFFICER	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Derek M Meisner	officer: SENIOR VP AND GENERAL COUNSEL	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michael Alfieri	officer: Principle Financial Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140